www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Hematology
All latest versions
6 June 2023
7 December 2022
7 June 2022
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ALL
ARI-0001
Brexucabtagene autoleucel
IND
Crisantaspase
Obecabtagene autoleucel
Ponatinib
IND
AML / MDS
Decitabine / cedazuridine
Eprenetapopt
Gilteritinib
IND
Iomab-B
Ivosidenib
Magrolimab
Quizartinib
Aggressive non-Hodgkin?s lymphoma
Acalabrutinib
IND
Axicabtagene ciloleucel
IND
Crizotinib
IND
Epcoritamab
Glofitamab
Ibrutinib
IND
Lisocabtagene maraleucel
IND
Loncastuximab tesirine
Pirtobrutinib
Polatuzumab vedotin
IND
Tafasitamab
Zamtocabtagene autoleucel
Zanubrutinib
IND
CLL
Acalabrutinib
Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Extension of the existing CLL indication to include combination treatment with venetoclax for previously untreated patients.
IND
Zanubrutinib
Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL).
IND
Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy
IND
CML
Asciminib
Hodgkin's lymphoma
Brentuximab vedotin
IND
Indolent non-Hodgkin?s lymphoma
Axicabtagene ciloleucel
IND
Epcoritamab
IND
Hypericin
Ibrutinib
IND
Lacutamab
Mosunetuzumab
Tisagenlecleucel-T
IND
Zanubrutinib
IND
Multiple Myeloma
Belantamab mafodotin
IND
Ciltacabtagene autoleucel
Daratumumab
IND
Elranatamab
Idecabtagene vicleucel
IND
Isatuximab
Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
IND
In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant.
IND
Ixazomib
IND
Melphalan flufenamide
Pepaxti, in combinatie met dexamethason, is geïndiceerd voor de behandeling van volwassen patiënten met multipel myeloom die minstens drie eerdere therapielijnen hebben gekregen, bij wie de ziekte refractair is voor ten minste één proteasoomremmer, één immunomodulerend middel, één antiCD38-monoklonaal antilichaam, en die tijdens of na hun laatste therapie ziekteprogressie vertoonden. Bij patiënten die eerder een autologe stamceltransplantatie hebben ondergaan, moet er tussen die transplantatie en de progressie ten minste drie jaar zijn verstreken.
IND
Extension of indication to include treatment of patients with Multiple Myeloma who have received at least two prior lines of therapies for PEPAXTI.
IND
Pomalidomide
G
Selinexor
IND
Talquetamab
Teclistamab
Thalidomide
G
Venetoclax
IND
Zevorcabtagene autoleucel
Myeloproliferative disorders
Avapritinib
IND
Bomedemstat
Momelotinib
Navitoclax
Pelabresib
Pemigatinib
IND
Other hematology
Lenzilumab
Luspatercept
IND
Obinutuzumab
IND
Stem cell transplants
Abatacept
IND
ECT-001-CB
Narsoplimab
Omidubicel
Plerixafor
G
Tabelecleucel
Treosulfan
IND
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English